Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Key developments in pancreatic cancer from ESMO 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.10.19
Views: 2054

Prof Eileen O'Reilly and Dr Ian Chau

Prof Eileen O'Reilly (Memorial Sloan Kettering Cancer Center, New York, USA) and Dr Ian Chau (The Royal Marsden NHS Foundation Trust, London, UK) discuss the key developments presented at ESMO 2019 surrounding pancreatic cancer.

The experts first examine the NEOLAP and GAP studies and discuss the multidisciplinary management for locally advanced disease.

Prof O'Reilly and Dr Chau also discuss the recent developments from the POLO trial, including health related quality of life in patients with a germ line BRCA mutation.

The experts conclude by exploring the results from the APACT trial in patients with surgically resected pancreatic adenocarcinoma.

This programme has been supported by an unrestricted educational grant from AstraZeneca.


Related videos

follow us

Oncology knowledge

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation